Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infltrating the conjunctiva in late-phase experimental ocular allergy

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 745-757

  Baiula, Monica ^a   Bedini, Andrea ^a   Baldi, Jacopo ^a   Cavet, Megan E ^b   Govoni, Paolo ^c   Spampinato, Santi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BAUSCH AND LOMB   (United States)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Allergic conjunctivitis; Eosinophil; Late phase response

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; EOSINOPHIL PEROXIDASE; EOTAXIN; GLUCOCORTICOID RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; MAPRACORAT; MESSENGER RNA; OVALBUMIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; GLUCOCORTICOID RECEPTOR; PENTANOL; QUINOLINE DERIVATIVE; R-1,1,1-TRIFLUORO-4-(5-FLUORO-2,3-DIHYDROBENZOFURAN-7-YL)-4-METHYL-2-(((2-METHYL-5-QUINOLYL)AMINO)METHYL)PENTAN-2-OL;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG STRUCTURE; EOSINOPHIL; GUINEA PIG; NONHUMAN; PROTEIN EXPRESSION; AGONISTS; ANIMAL; CONFORMATION; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MALE; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; BENZOFURANS; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; EOSINOPHILS; GUINEA PIGS; HUMANS; MALE; MOLECULAR CONFORMATION; PENTANOLS; QUINOLINES; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902532439     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S62659     Document Type: Article

References (55)

1. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153(Suppl 1):17-21.
2. Bielory B P, O'Brien T P, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol. 2012;90:399-407.
3. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10:478-485.
4. Irkec MT, Bozkurt B. Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2012;12:534-539.
5. Chauhan S, Leach CH, Kunz S, Bloom J W, Miesfeld RL. Glucocorticoid regulation of human eosinophil gene expression. J Steroid Biochem Mol Biol. 2003;84:441-452.
6. Bielory B P, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2010;10:469-477.
7. De Bosscher K, Haegeman G, Elewaut D. Targeting infammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. 2010;10:497-504.
8. Ratman D, Vanden Berghe W, Dejager L, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol. 2013;380:41-54.
9. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 2007;72:799-809.
10. Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134:54-67.
11. Newton R. Anti-infammatory glucocorticoids: changing concepts. Eur J Pharmacol. 2014;724:231-236.
12. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol. 2010;120:96-104.
13. Schäcke H, Zollner TM, Döcke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of infammatory skin diseases. Br J Pharmacol. 2009;158: 1088-1103.
14. Bodor N, Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241-3260.
15. Proksch J W, Lowe ER, Ward K W. Ocular pharmacokinetics of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbits and monkeys. Drug Metab Dispos. 2011;39:1181-1187.
16. Shafee A, Bucolo C, Budzynski E, Ward K W, López FJ. In vivo ocular effcacy profle of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci. 2011;52:1422-1430.
17. Pfeffer BA, DeWitt CA, Salvador-Silva M, Cavet ME, López FJ, Ward K W. Reduced myocilin expression in cultured monkey trabe-cular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids. Invest Ophthalmol Vis Sci. 2010;51: 437-446.
18. Baiula M, Spartà A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis. 2011;17:3208-3223.
19. Cavet ME, Volhejn S, Harrington KL, Zhang JZ. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fbroblasts and epithelial cells. Mol Vis. 2013;19: 1515-1525.
20. Cavet ME, Harrington KL, Ward K W, Zhang JZ. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis. 2010;16:1791-1800.
21. Chambless SL, Trocme S. Developments in ocular allergy. Curr Opin Allergy Clin Immunol. 2004;4:431-434.
22. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med. 2005;11:35-42.
23. Abu El-Asrar AM, Struyf S, Al-Kharashi SA, Missotten L, Van Damme J, Geboes K. Chemokines in the limbal form of vernal keratoconjunctivitis. Br J Ophthalmol. 2000;84:1360-1366.
24. Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology. 2003;110: 487-492.
25. Kvarnhammar AM, Cardell LO. Pattern-recognition receptors in human eosinophils. Immunolog y. 2012;136(1):11-20.
26. Duffn R, Leitch AE, Fox S, Haslett C, Rossi AG. Targeting granulocyte apoptosis: mechanisms, models, and therapies. Immunol Rev. 2 010;236: 28-40.
27. McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. ScientifcWorldJournal. 2007;7:1165-1181.
28. Druilhe A, Létuvé S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis. 2003;8: 481-495.
29. Baiula M, Bedini A, Carbonari G, Dattoli SD, Spampinato S. Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis. Front Pharmacol. 2012;3:203.
30. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ. Eosinophil apoptosis and the resolution of airway infam-mation in asthma. Am J Respir Crit Care Med. 1996;154:237-243.
31. Uller L, Emanuelsson CA, Andersson M, Erjefält JS, Greiff L, Persson CG. Early phase resolution of mucosal eosinophilic infammation in allergic rhinitis. Respir Res. 2010;11:54.
32. Uller L, Persson CG, Erjefält JS. Resolution of airway disease: removal of infammatory cells through apoptosis, egression or both? Trends Pharmacol Sci. 2006;27:461-466.
33. Qasem AR, Bucolo C, Baiula M, et al. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008;76:751-762.
34. Kato M, Imoto K, Miyake H, Oda T, Miyaji S, Nakamura M. Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs. J Pharmacol Sci. 2004;95: 435-442.
35. Walker RA. Quantifcation of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406-410.
36. Kelly MM, King EM, Rider C F, et al. Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide. Br J Pharmacol. 2012;165:1737-1747.
37. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identifcation of programmed cell death in situ via specifc labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
38. Uller L, Andersson M, Greiff L, Persson CG, Erjefält JS. Occurrence of apoptosis, secondary necrosis, and cytolysis in eosinophilic nasal polyps. Am J Respir Crit Care Med. 2004;170:742-747.
39. Uller L, Lloyd CM, Rydell-Törmänen K, Persson CG, Erjefält JS. Effects of steroid treatment on lung CC chemokines, apoptosis and transepithelial cell clearance during development and resolution of allergic airway infammation. Clin Exp Allergy. 2006;36:111-121.
40. Kubo S, Kobayashi M, Masunaga Y, et al. Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs. Eur Respir J. 2005;26:993-1001.
41. Lacy HM, Bowlin AK, Hennings L, Scurlock AM, Nagarajan UM, Rank RG. Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections. Infect Immun. 2011;79: 1889-1897.
42. Choi SH, Bielory L. Late-phase reaction in ocular allergy. Curr Opin Allergy Clin Immunol. 2008;8:438-444.
43. Zhang JZ, Cavet ME, VanderMeid KR, Salvador-Silva M, López FJ, Ward K W. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-infammatory properties in human ocular cells. Mol Vis. 2009;15:2606-2616.
44. Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000;406:325-332.
45. Kawabori S, Soda K, Perdue MH, Bienenstock J. The dynamics of intestinal eosinophil depletion in rats treated with dexamethasone. Lab Invest. 1991;64:224-233.
46. Uller L, Persson CG, Källström L, Erjefält JS. Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment. Am J Respir Crit Care Med. 2001;164:1948-1956.
47. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163:29-43.
48. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005;18:331-342.
49. Lu NZ, Collins JB, Grissom SF, Cidlowski JA. Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol. 2007;27:7143-7160.
50. Wu I, Shin SC, Cao Y, et al. Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes. Cell Death Dis. 2013;4:e453.
51. Catley M. Dissociated steroids. ScientificWorldJournal. 2007;7: 421-430.
52. Clark AR. Anti-infammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol. 2007;275:79-97.
53. Bausch & Lomb Incorporated. Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01289431?term=mapracorat&rank=6. NLM identifer: NCT01289431. Accessed March 20, 2014.
54. Bausch & Lomb Incorporated. Study to Assess the Safety and Effcacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01163643?term=nct01163643&rank=1. NLM identifer: NCT01163643. Accessed March 20, 2014.
55. Bausch & Lomb Incorporated. Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Infammation and Pain Following Cataract Surgery. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01591161?term=mapracorat&rank=3. NLM identifier: NCT01591161. Accessed March 20, 2014.